Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma

DOI Web Site PubMed

Bibliographic Information

Other Title
  • 自家末梢血幹細胞移植後のbrentuximab vedotin維持療法が奏効した高リスクHodgkinリンパ腫
  • 症例報告 自家末梢血幹細胞移植後のbrentuximab vedotin維持療法が奏効した高リスクHodgkinリンパ腫
  • ショウレイ ホウコク ジカ マッショウケツ カンサイボウ イショク ゴ ノ brentuximab vedotin イジ リョウホウ ガ ソウコウ シタ コウリスク Hodgkin リンパシュ

Search this article

Description

<p>A 56-year-old woman was diagnosed with classical Hodgkin lymphoma in December 2012. She achieved complete remission (CR) with six cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD). In March 2015, she experienced a relapse marked by high fever, respiratory discomfort, and pain in the left thigh owing to tumor involvement of the femur. She was treated with one cycle of brentuximab vedotin (BV), followed by irradiation of the left femoral lesion. She achieved partial remission (PR) but developed recurrence after the third cycle of BV. She achieved PR again with two cycles of standard bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) regimen; therefore, autologous stem cell transplantation (ASCT) was performed. Because the dosing interval used for BV therapy was longer than that in the recommended schedule, we could not definitively attribute her recurrence to BV resistance. Moreover, she maintained a good performance status after recurrence during subsequent cycles of BV therapy. Because of attaining PR after ASCT, she subsequently received a total of 12 BV cycles for consolidation. She achieved CR 3 months after ASCT and has remained in CR until 29 months. For patients who show relapse after initial BV therapy, retreatment with BV should be carefully considered. Patients who show relapse after achieving at least PR with initial BV therapy are potential candidates for post-ASCT BV maintenance therapy to reduce their tumor burden.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 59 (8), 1002-1006, 2018

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top